



# MAIL STOP PCT $_{\tau,\mathcal{F}^{\omega}}$

Docket No.

295086US0PC7

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Kouichi TAMURA, et al.

SERIAL NO: 10/591,287

GAU:

FILED:

August 31, 2006

EXAMINER:

FOR:

ANTI FK778ANTIBODIES AND HIGH SENSITIVE IMMUNOASSAY METHODS

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

#### REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

#### RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

## **CERTIFICATION**

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

### **DEPOSIT ACCOUNT**

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Norman F. Oblo

Registration No. 24,618

Surinder Sachar

Registration No. 34,423

Customer Number

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

NOV 2 9 2006 SHEET 1 OF 1

					— <i>Y</i> /—			
Form PTO 1449 (Modified)			ATTY DOCKET NO. 295086US0PCT		SERIAL NO.			
			295086US0PCT			281		
				APPLICANT				
LIST OF REFERENCES CITED BY APPLICANT				Kouichi TAMURA, et al.				
				FILING DATE		GROUP		
				August 31, 2006				
				U.S. PATENT DOCUMENTS		l		
=>///		DOO! ILVELIT	Τ	J. J	Т	Loup	EII ING DATE	
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
	AA							
	AB							
	AC							
	AD	<del>-</del>	l					
	AE	· · · · · · · · · · · · · · · · · · ·	<del> </del>					
		,	<del></del>	7.4				
	AF							
	AG							
	AH							
	ΑI							
	AJ							
	AK							
	AL							
	AM							
	AN							
	AN		L	10 - 10 - 10 - 10 - 10 - 10 - 10 - 10 -				
			FO	REIGN PATENT DOCUMENTS				
		DOCUMENT	DATE	COUNTRY		TRANSLATION		
		NUMBER	DATE			YES NO		
	AO	03/086391	10/23/03	wo			NO	
	AP	# **···						
	AQ							
	AR					<del>                                     </del>		
		· · · · · ·				<b></b>		
	AS	-						
	AT		<u> </u>					
	AU		L	W	_	<u> </u>		
	AV	_						
		OTHER RE	FERENCES (	Including Author, Title, Date, Pertine	nt Pages, e	etc.)		
	Γ	BIRSAN T et al "In v	vivo nharmaco	kinetic and pharmacodynamic evaluation	n of the ma	lononitrilan	nide FK778 in non-human	
	AW	BIRSAN, T. et al., "In vivo pharmacokinetic and pharmacodynamic evaluation of the malononitrilamide FK778 in non-human primates", Transplant International, Vol. 16, No. 5, Pages 354-360, 2003.						
	JOHNSTON, Atholl et al., " Immunosuppressant drugs- the role of therapeutic drug monitoring", Brtish Journal of Clinical							
	AX							
	ALAK, Ala M., "Measurement of Tacrolimus (FK506) and Its Metabolites: A Review of Assay Development and Application in							
	AY	Therapeutic Drug Monitoring and Pharmacokinetic Studies", Therapeutic Drug Monitoring, Vol. 19, No.3, Pages 338-351, 1997.						
_		DETERS, Michael et al., " Liquid chromatography/mass spectrometry for						
		DETERS, Michael et a						
	AZ	DETERS, Michael et a	toring of immu	nosuppressants", Analytica Chimica	Add	itional Refe	erences sheet(s) attached	
Examiner	AZ	DETERS, Michael et a therapeutic drug monit	toring of immu	nosuppressants", Analytica Chimica	┼ ̄	itional Refe	erences sheet(s) attached	
-	<u> </u>	DETERS, Michael et a therapeutic drug monit Acta, Vol. 492, No. 1-2	toring of immu 2, Pages 133-1	nosuppressants", Analytica Chimica	Date Co	nsidered		

U.S. PCT Application Serial No: 10/591,287

Filed: August 31, 2006 Kouichi TAMURA, et al. Docket No. 295086 US

## STATEMENT OF RELEVANCY

- 1) References AW AZ have been cited in the International Search Report. A copy of these references is being submitted herewith.
- 2) References have been cited in the corresponding Search Report. A copy of these references is being submitted herewith.
- 3) Reference AO is discussed in the specification. A copy of this reference is being submitted herewith.
- 4) References are additional prior art known to Applicant. A copy of these references is being submitted herewith.